Posted by


 Comments of Fred A. Baughman Jr., MD on: Grants from NIH and Industry for US
 Clinical Trials to Exceed $4 Billion in 2000 According to CenterWatch Research  Boston, MA ,
 November 2000 (From the November issue of the CenterWatch newsletter)

 CONTACT:        Annick de Bruin, Research Manager
 CenterWatch (617) 856-5956

 Grants from NIH and Industry for
 US Clinical Trials to Exceed $4 Billion
 in 2000 According to CenterWatch Research  Boston,
 MA , November 2000: Total
 spending on clinical trials in 2000, from all
 sources, is expected to reach
 as much as $4.5 billion in the United States. More
 than 80% of this spending
 will come from pharmaceutical, biotechnology and
 medical device companies.
 These findings are based on primary and secondary
 research conducted by
 CenterWatch, a Boston-based publisher focusing on
 the clinical trials

[Fred A. Baughman Jr., MD:
Psychopharmacology—psychiatric drugs—represent the biggest sector of the pharmaceutical
industry, bigger than antibiotics, bigger than all drugs for all forms of arthritis. It
also differs from all branches of pharmacology in that the persons/ ‘patients’,
‘treated’/drugged, have no actual disease; they are normal, although
emotionally/behaviorally/psychologically troubled. With industry funding 80% of the
research, is it a surprise to find them calling such things ‘diseases’ due to ‘chemical
imbalances’ for no purpose other than to make ‘patients’ of normal persons and to get those
‘patients’ to believe in the logic and ‘science’ that would have them take ‘chemical
balancers’—pills, to balance their ‘chemical imbalance.’

In that they invent diseases out of thin air and convince legislators and judges that
persons having them should be treated against their own will, can you possibly bring
yourself to believe that trials of their drugs, which they author, fund, hire for, and
conduct will possibly conclude other than that the drug—their product--is ‘safe and

They—especially those in psychopharmaceutical drug trials- are spending an astronomical 4.5
billion dollars on clinical trials, not so much to discover a wonder drug, to work wonders,
to cure diseases, or heal diseased, broken bodies—but to create a ‘scientific’/ ‘medical’/
‘therapeutic’ literature’ all of which says, not once, but repeatedly, that their drug is
‘safe and efficacious’ whether it is or not, whether it is crippling and deadly or not.
Such is the corporate, dollars-only, mentality and ethic that prevails today, that
guides/rules the government and dependent, bought-and-paid-for medical academia and the
whole of the medical profession here in the US. It would be of particular interest to know
what percent of the 4.5 billion dollars are being spend for psychiatric drug trials. This
should be an easy figure to get.]

 "The results of our analysis show a very robust
 market that is growing 18%
 annually," said Annick de Bruin, research manager.
 "And pharmaceutical
 companies make up the lion's share of total
 spending. Only about 20 cents of
 every clinical grant dollar is spent by the
 government for clinical trials
 involving human subject participation," she said.
 Reported in the November
 issue of the CenterWatch newsletter, clinical grant
 market estimates capture
 the total spending on clinical trials involving
 study volunteers and medical
 The estimates include historical data on spending
 levels by industry and by
 the National Institutes of Health (NIH). The
 analysis also includes revised
 1999 estimates of the market distribution for
 clinical trial services by
 academic institutions and independent for-profit
 investigative sites.  "The
 most recent analysis is a continuation of work that
 we have been doing since
 1995 with one exception," said Ken Getz, CenterWatch
 president and
 publisher. "To our knowledge, this report presents
 the first published
 estimates of NIH spending for comparable clinical
 trials to those sponsored
 by industry. This was a very difficult part of the
 analysis. And we hope to
 refine it based on additional feedback from the NIH
 and academic


Leave a Reply

  • (will not be published)